
- /
- Supported exchanges
- / US
- / NAMS.NASDAQ
NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS NASDAQ) stock market data APIs
NewAmsterdam Pharma Company N.V. Ordinary Shares Financial Data Overview
NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases. The company also develops Obicetrapib which is in Phase 2a clinical trial for Alzheimer's disease. NewAmsterdam Pharma Company N.V. is headquartered in Naarden, the Netherlands.
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Or get access to advanced financial data starting only $19.99
Get NewAmsterdam Pharma Company N.V. Ordinary Shares data using free add-ons & libraries
Get NewAmsterdam Pharma Company N.V. Ordinary Shares Fundamental Data
NewAmsterdam Pharma Company N.V. Ordinary Shares Fundamental data includes:
- Net Revenue: 47 140 K
- EBITDA: -189 582 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
End-of-day & Earnings data
Get NewAmsterdam Pharma Company N.V. Ordinary Shares Earnings data
What’s included:
- Latest Release: 2025-05-12
- EPS/Forecast: -0.4364
Get NewAmsterdam Pharma Company N.V. Ordinary Shares End-of-day data
EOD Historical Data package for
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
NewAmsterdam Pharma Company N.V. Ordinary Shares News

New Amsterdam Pharma director Topper buys shares worth $69k
Director James N. Topper of NewAmsterdam Pharma Co N.V. (NASDAQ:NAMS), a $2.1 billion market cap pharmaceutical company, recently purchased shares of the company’s stock. On June 24, 2025, Topper ac...


Citi initiates coverage on biotech amid improving sentiment in sector
Investing.com -- Citi initiated coverage on small- and mid-cap biotechnology companies on early signs of improving sentiment in a sector weighed down this year by policy uncertainty and weak investor ...

Citi initiates coverage on biotech amid improving sentiment in sector
Investing.com -- Citi initiated coverage on small- and mid-cap biotechnology companies on early signs of improving sentiment in a sector weighed down this year by policy uncertainty and weak investor...

NewAmsterdam Pharma's SWOT analysis: stock poised for cardiovascular breakthrough
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) is making waves in the cardiovascular drug market with its lead asset, obicetrapib, a cholesteryl ester transfer protein (CETP) inhibitor. As the company...
Or get access to advanced financial data starting only $19.99
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.